NRAS Mutation Detection by Pyrosequencing
2003123
 
Additional Technical InformationAdditional Technical Information
Ordering Recommendation
Predicts response to anti-EGFR and MAPK pathway therapies in a variety of malignancies (eg, melanoma and colorectal cancer).
Mnemonic
NRAS
Methodology
Polymerase Chain Reaction/Pyrosequencing
Performed
Sun-Sat
Reported
10-12 days
New York DOH Approval Status
This test is New York DOH approved.
Specimen Required
Patient Preparation
 
Collect
Tumor tissue.  
Specimen Preparation
Formalin fix (10 percent neutral buffered formalin) and paraffin embed tissue. Protect from excessive heat. Transport tissue block or 5 unstained 5 micron slides. (Min: 3 slides). Transport block and/or slide(s) in a tissue transport kit (ARUP supply # 47808) available online through eSupply using ARUP Connect™or contact ARUP Client Services at (800) 522-2787.  
Storage/Transport Temperature
Room temperature. Ship in cooled container during summer months.  
Unacceptable Conditions
Frozen specimens. Specimens fixed/processed in alternative fixatives (alcohol, Prefer®) or heavy metal fixatives (B-4 or B-5). Decalcified specimens.  
Remarks
Include surgical pathology report. Tissue block will be returned after testing.  
Stability
Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable  
Reference Interval
Interpretive Data
Refer to report.

See Compliance Statement B: www.aruplab.com/CS
Note
This assay detects mutations in codons 12, 13, and 61.
CPT Code(s)
88381; 81404
Components
Component Test Code*Component Chart Name
2002148Block ID
2003124NRAS Mutation Detection, Pyrosequencing
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, contact interface support at interface.support@aruplab.com.
Cross References
  • Anti-EGFR therapy resistance
  • Codon 12,13
  • Codon 61
  • N-RAS
  • RAS Mutation Analysis, Thyroid Cancer